The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 8 June 2004, www.theannals.com, DOI 10.1345/aph.1D626.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1236-1242. DOI 10.1345/aph.1D626
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, L. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, L. A

FORMULARY FORUM

Omalizumab: A Novel Therapy for Allergic Asthma

Lorrie A Davis, PharmD

Drug Information Practice Resident, Department of Pharmacy, University of Virginia Health System, PO Box 800674, Charlottesville, VA 22908-0674, fax 434/982-1682, ld4z{at}virginia.edu

Reprints: Lorrie A Davis PharmD

OBJECTIVE: To review the pharmacology, efficacy, and safety of omalizumab, focusing on the treatment of allergic asthma.

DATA SOURCES: A MEDLINE search (1966–November 2003) was conducted using the key words omalizumab, Xolair, and Rhu-MAB25, with studies limited to those in humans and published in English. References of identified articles were reviewed for additional citations.

STUDY SELECTION AND DATA EXTRACTION: Clinical trials evaluating the pharmacology, efficacy, and safety of omalizumab for treatment of allergic asthma in patients aged ≥12 years were selected. Clinical trials examining utility in pediatric patients were also reviewed.

DATA SYNTHESIS: Omalizumab's ability to form complexes with unbound immunoglobulin E (IgE) translates into decreased unbound serum IgE levels and high-affinity IgE receptors on basophils, as well as attenuation of early and late allergic response in patients with allergic asthma. Results of clinical trials demonstrated that omalizumab administered subcutaneously is a safe and effective treatment for moderate to severe allergic asthma. Generally, omalizumab has a mild adverse effect profile. Omalizumab may be particularly useful for treatment of moderate to severe allergic asthma in patients who are poorly controlled on conventional therapy, experience adverse effects secondary to high-dose or prolonged corticosteroid treatment, or who have frequent exacerbations because of poor medication adherence. The high cost associated with omalizumab treatment may be prohibitive for some patients, thereby limiting its utility.

CONCLUSIONS: Omalizumab is a safe and effective therapy for treatment of moderate to severe allergic asthma in difficult-to-treat, high-risk patients.

Key Words: allergic asthma, omalizumab, Xolair

Published Online, June 8, 2004. www.theannals.com, DOI 10.1345/aph.1D626

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-024-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.